Anidulafungin Articles
Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid
22 December 2009
Health Canada approves Pfizer's Eraxis
3 December 2007
US FDA OKs Pfizer's Eraxis for first launch
27 February 2006
Vicuron amends its IND for anidulafungin
6 June 2005
Vicuron and Pfizer extend collaboration
18 April 2005
Vicuron's anti-fungal "superior" to Pfizer's
14 February 2005
Vicuron to reduce costs due to anidulaflungin delay
28 June 2004
Vicuron's antifungal faces delay in USA
31 May 2004
FDA requires more time to review Vicuron's antifungal agent
2 February 2004
Vicuron antifungal promising in Phase II
19 May 2003
Vicuron files NDA for anidulafungin in USA
5 May 2003
Positive PH II results for Versicor's anidulafungin
24 March 2003
Losses double at Versicor
25 February 2002
Versicor starts pivotal trials of antifungal
14 January 2002
Showing 1-17 of 17 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
